Completed PHASE1 INTERVENTIONAL 1-arm NCT02690337

Study of DS-1123a in Advanced Solid Tumours

Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-1123a in Subjects With Advanced Solid Tumors

Sponsor: Daiichi Sankyo Co., Ltd.

Conditions Advanced Solid Malignant Tumors

Interventions DS-1123

Updated 11 times since 2017 Last updated: Dec 20, 2018 Started: Jan 31, 2016 Primary completion: Nov 30, 2017 Completion: Nov 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Malignant Tumors and is currently completed. Daiichi Sankyo Co., Ltd. leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2024 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Mar 2024 [monthly]

Completed PHASE1
Jan 2019 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 6 earlier versions

Jun 2018 — Jan 2019 [monthly]

Completed PHASE1
Jan 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Nov 2017 — Jan 2018 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Sep 2017 — Nov 2017 [monthly]

Recruiting PHASE1
May 2017 — Sep 2017 [monthly]

Recruiting PHASE1
Jan 2017 — May 2017 [monthly]

Recruiting PHASE1

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo Co., Ltd.

Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan